Mindera Health is collaborating with University of Pennsylvania researchers to investigate why quinacrine helps some patients with cutaneous lupus—and whether skin biomarkers can predict who will respond. Funded by the Lupus Research Alliance, the study will use Mindera’s minimally invasive skin-sampling patch to track molecular changes during treatment, and marks the first academic collaboration to deploy Subtilitas, the precision translational medicine platform Mindera Health launched earlier this year with Mountaineer Biosciences.
The collaboration centers on Mindera Health's Dermal Biomarker Patch, an FDA-registered minimally invasive device that captures molecular signals from skin without biopsy, and the Subtilitas platform, which integrates non-invasive skin sampling, next-generation sequencing (NGS), and machine learning to characterize immune and skin disease biology. Penn principal investigator Victoria P. Werth, MD, will deploy these tools in a prospective, randomized, placebo-controlled trial in which hydroxychloroquine (HCQ)-nonresponsive CLE patients receive HCQ plus quinacrine or HCQ plus placebo for 12 weeks, followed by 12 weeks of open-label HCQ plus quinacrine for both arms. The study, conducted in collaboration with Ben Chong, MD at UT Southwestern, will serially analyze blood and skin samples throughout the 24-week trial to identify biomarkers that distinguish quinacrine responders from nonresponders.
The scientific hypothesis driving the study holds that quinacrine works in HCQ-nonresponsive patients by antagonizing toll-like receptor 8 (TLR8) in myeloid dendritic cells, shutting down an inflammatory cascade that HCQ does not suppress. Werth's lab has previously published work identifying inflammatory mediators selectively suppressed by quinacrine, providing the mechanistic basis for this TLR8-focused investigation.
Mindera Health's prior commercial activity has focused on precision medicine applications in dermatology, including a 2024 program with a pharmacy benefit manager targeting moderate-to-severe psoriasis management using its Dermal Biomarker Patch technology. The CLE collaboration extends the platform into autoimmune skin disease and into the academic research setting, where no US FDA-approved CLE-specific therapy has emerged in more than 60 years. Approximately half of CLE patients fail first-line HCQ, leaving quinacrine as a second-line option whose two-month-or-longer response timeline has historically made patient selection a trial-and-error process. The study's biomarker discovery objective is to enable upfront identification of likely quinacrine responders before treatment begins.
Spot something wrong? Report an issue with this article